[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Evaluation of the Effects of Ketorolac 15mg IV Versus 30mg IV on Duration of Analgesia in Patients Who Present to the Emergency Department With Renal Colic


Description

This is a prospective interventional study examining the effect of ketorolac at doses of 15mg versus 30 mg for duration of analgesia in emergency department patients with suspected renal colic.Pain is a common emergency department complaint. With various types of analgesics available, the optimal drug is one that provides adequate pain management with minimal side effects. The goal is to effectively treat the patient while maintaining adequate flow in the emergency department. In cases of moderate to severe pain in emergency departments, opioids have been the gold standard.1 Opiates, such as morphine, are associated with side effects that can be distressing to the patient, as well as, costly to the department. Prescribing opiates includes a reluctance in administering sufficient opioid dosing due to fear of tolerance and dependency.2 It has been demonstrated in other studies that the standard dosing of ketorolac is higher than needed to achieve analgesia but have failed to show to wha

Trial Eligibility

Inclusion Criteria: Patients will be included if they present to the Emergency Department with (all of the following): * Adult emergency department patients \< 65 years old * Complaint of flank pain * Pain score of 4 or greater on the 0-10 NRS * Determination of treatment with IV ketorolac Exclusion Criteria: Patients will be excluded if any of the following apply: * Allergy to ketorolac * Pregnant patients * Previously received analgesic medications within 4 hours prior to administration of ketorolac in our ED * Known or stated history of renal insufficiency (eGFR \< 50 ml/min/1.73 m2) * Body weight \< 50 kg * Age greater than 65 years * Patients that do no read/write Spanish or English

Study Info

Organization

Hackensack Meridian Health


Primary Outcome

Change in pain scale post ketorolac administration


Outcome Timeframe At 120 minutes from medication administration

NCTID NCT05776953

Phases PHASE4

Primary Purpose TREATMENT

Start Date 2023-12-21

Completion Date 2024-12-20

Enrollment Target 86

Interventions

DRUG Ketorolac

Locations Recruiting

Hackensack Univarsity medical Center

United States, New Jersey, Hackensack


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Kidney Disease delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.